Wanbin Zhang Group

Modern Organic Synthesis and Catalysis
  Recent Progress and News  

"Ir/Cu Dual Catalysis: Enantio- and Diastereodivergent Access to α,α-Disubstituted α-Amino Acids Bearing Vicinal Stereocenters". Recently published by J. Am. Chem. Soc. Congratulations!


"Stereoselective and Site-specific Allylic Alkylation of Amino Acids and Small Peptides via a Pd/Cu Dual Catalysis". Recently published by J. Am. Chem. Soc. Congratulations!


"An Ir/Zn Dual Catalysis for Enantio- and Diastereodivergent α-Allylation of α-Hydroxyketones". Recently published by J. Am. Chem. Soc. Congratulations!



Merck & Co. received the 2020 Green Chemistry Challenge Awards for improving the process used to produce certain antiviral drugs (asymmetric phosphorylation using the chiral bicyclic imidazole catalyst).

Our bicyclic imidazazole nuleophilic catalyst (J. Am. Chem. Soc., 2010, 132, 15939-15941.) has been used and modified by Merck to prepare a chiral phosphoramidate, MK-3682, which is currently in Phase III clinical trials for treating hepatitis C. This work was published recently in Science (Science, 2017, 356, 426-430.) and highlighted by C&EN (C&EN, 2017, 95, 5.) as well as X-MOL News.


Our research about "Highly Efficient Synthesis of Qinghaosu (Artemisinin)" was reported by CCTV News (2012-08-14). This research was chosen as one of the "Top Ten Important Scientific and Technological News of China" (2012-12-28) and also chosen as one of the "Shanghai's Top Ten Scientific and Technological Achievements in 2012" (2013-05-02). The pilot plant test of 10 kilogram scale (500 L) has been successfully completed and our technology has been transferred to a company(2016-12-31).


All positions are available!

上海市手性药物分子工程重点实验室 | 上海交通大学化学化工学院 | 上海交通大学药学院

Copyright © 2008 Laboratory of Wanbin Zhang All rights reserved